Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands.

Founded in 2015, Accure is wholly focused on the elimination of acne through innovative and disruptive non-systemic solutions. Recent studies have also shown a significant link between acne and depression, as well as anxiety.

"This achievement represents the culmination from two decades of clinical research led by The Wellman Center for Photomedicine at Massachusetts General Hospital," notes Christopher Carlton, Chairman, Chief Executive Officer, and co-Founder of Accure. "This milestone brings an impactful solution to millions of acne sufferers in Europe."

Accure's clinical and technical development teams represent an unmatched collaboration of engineering acumen and clinical expertise, led by Prof. Rox Anderson, MD, co-Founder of Accure. 

Preliminary clinical data from Accure's on-going IRB-approved Face Trial demonstrates a reduction of more than 80 percent in inflammatory lesions at three months after treatment. Accure has compiled hundreds of in vivo human skin histology samples depicting a significant effect on sebaceous glands.  Dr. Emil Tanghetti, a principal investigator of the Accure Laser, states, "I am impressed with Accure's safety-first, data-driven approach. The clinical results thus far are exciting, and the uniqueness of the proprietary temperature and operator feedback control systems makes this much more than just a new laser wavelength. I look forward to on-going advances with this platform."

Accure is partnered with Quanta System, S.p.A (El.En. Group), based in Milan. Quanta has contributed substantial resources and expertise to the development of the Accure Laser and will be the exclusive manufacturing partner of Accure as commercial activities accelerate. The laser platform has been designed with highly unique and innovative technology, resulting in over 14 granted, pending, and provisional patents issued to Accure through exclusive global licenses. 

The Accure Laser is the first commercial product to be released by Accure in Europe, available in the second half of 2020 in several key markets.